Paris: Sanofi has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has ...

Background: Gastroesophageal reflux occurs mainly during the daytime in patients with Los Angeles grade A esophagitis, but predominantly during the night in patients with grade C and D esophagitis.

The gastrointestinal microbiome remains an explosively increasing topic of study, assessing the potentially pivotal roles of the microbiome in maintaining health or causality in disease pathogenesis.

The following is a summary of “Gastrointestinal dysmotility is associated with proton pump inhibitor refractory esophagitis in patients with systemic sclerosis,” published in the September 2024 issue ...

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, ...

CALY-002 is under development for the treatment of eosinophilic esophagitis, celiac disease and unspecified dermatological disorders. It is a fully-humanized monoclonal antibody also administered ...

Eupraxia Pharmaceuticals has disclosed additional positive data from its Phase Ib/IIa RESOLVE clinical trial of EP-104GI in treating eosinophilic esophagitis (EoE). The multicentre, open-label ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...

A reduction in SDI is a positive outcome for the RESOLVE trial. 2. In the Eosinophilic Esophagitis Histology Scoring System, or EoEHSS, grade indicates the severity of each of the eight ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion ...